Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series - 19/06/20
Funding sources: None. |
|
Conflicts of interest: This was an investigator-initiated trial. The drug adalimumab biosimilar (Exemptia) was provided by Zydus Biovation (division of Cadila Health Care) free of cost to all patients. Zydus Biovation had no interference in the design, conduct, and analysis of the study. |
|
IRB approval status: Reviewed and approved by All India Institute of Medical Sciences Ethics Committee, New Delhi (approval reference number IEC-83/08.01.2016, RP-11/2016). |
Vol 83 - N° 1
P. 248-251 - juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?